Crystal's Coder Hub🧬 [ICD-10-CM] C61 — Malignant Neoplasm Of Prostate
Billable Code Confirmed
[ICD-10-CM] C61 is a valid, billable 3-character ICD-10-CM code for FY2026. The character structure is: C (Chapter 2 — Neoplasms), 6 (male genital organ block C60-C63), and 1 (prostate-specific category). No additional characters are required or available — C61 is complete as-is.
Non-Billable / Closely Related Codes — Know the Difference
- ❌
Z85.46— Personal history of malignant neoplasm of prostate — use only when prior prostate cancer is resolved/treated with no current active disease- ❌
D07.5— Carcinoma in situ of prostate — use for in situ prostatic neoplasm, NOT active invasive malignancy- ❌
C63.7— Malignant neoplasm of seminal vesicle — different anatomic primary site; do not substitute for C61Always submit C61 when the provider documents active prostate cancer, malignant neoplasm of prostate, or prostatic adenocarcinoma as a current condition.
Clinical Context: Active Disease vs. History
ICD-10-CM C61 is reserved for active, invasive malignant neoplasm of the prostate. Once a patient’s prostate cancer is treated and the provider documents no evidence of active disease, the appropriate code shifts to Z85.46 (personal history). This distinction carries major HCC implications — C61 maps to HCC 12 under CMS-HCC v28, while Z85.46 carries no HCC weight.
Code Classification
ICD-10-CM Diagnosis Code — wRVU, assistant payable, and global period fields are not applicable to this diagnosis code. For associated inpatient procedures, refer to the ICD-10-PCS Crosswalk section. For outpatient/profee procedures, refer to the CPT Codes section.
🔍 Code Description
[ICD-10-CM] C61 classifies malignant neoplasm of prostate — the primary site code for active, invasive cancer arising from the prostate gland. This code encompasses prostatic adenocarcinoma (by far the most common histology), as well as other primary malignant histologies arising from the prostate unless a more specific code exists.
The prostate gland is part of the male reproductive system, situated inferiorly to the bladder and surrounding the proximal urethra. Prostate cancer is the most common non-skin cancer in American men, and its clinical management ranges from active surveillance to radical prostatectomy, radiation, brachytherapy, androgen deprivation therapy (ADT), and chemotherapy depending on grade, stage, and hormone sensitivity. When coding C61, the coder should also identify and separately code documented metastatic sites, hormone sensitivity status, and any post-treatment PSA elevation per ICD-10-CM instructional notes.
🌳 Code Tree / Hierarchy
C00-D49 Neoplasms ❌ Non-billable chapter header
│
└── C00-C96 Malignant neoplasms ❌ Non-billable block header
│
└── C60-C63 Malignant neoplasms of male genital organs ❌ Non-billable block header
│
├── C60 Malignant neoplasm of penis ✅ Billable
├── C61 Malignant neoplasm of prostate ◀ THIS CODE ✅ Billable
├── C62 Malignant neoplasm of testis ✅ Billable (with laterality)
└── C63 Malignant neoplasm of other and unspecified male genital organs ❌ Non-billable header
│
├── C63.0 Malignant neoplasm of epididymis ✅ Billable (with laterality)
├── C63.1 Malignant neoplasm of spermatic cord ✅ Billable (with laterality)
└── C63.7 Malignant neoplasm of seminal vesicle ✅ Billable
No Laterality for C61
Unlike testicular (C62) or epididymal (C63.0) malignancies, the prostate is a midline structure — C61 has no laterality axis. The code is complete at 3 characters. All specificity work for prostate cancer is achieved through additional codes for metastatic sites, hormone sensitivity, and post-treatment PSA status.
✅ Includes
The following clinical terms and scenarios map to C61 when documented as active invasive disease:
- Prostate cancer (active)
- Prostatic adenocarcinoma (primary)
- Malignant neoplasm of prostate gland
- High-grade prostatic carcinoma under active treatment
- Castration-resistant prostate cancer (CRPC) — still C61; add Z19.2 for hormone resistance if documented
- Hormone-sensitive prostate cancer (HSPC) — still C61; add Z19.1 for hormone sensitivity
❌ Excludes
Excludes 1 — Cannot Be Coded as the Same Primary Site
| Code | Description | Note |
|---|---|---|
| C63.7 | Malignant neoplasm of seminal vesicle | Mutually exclusive primary site — if pathology confirms seminal vesicle as the primary tumor origin, use C63.7, not C61. |
Excludes 1 Violation Risk
A coder may assign C61 when the operative or pathology report identifies the seminal vesicle as the true primary site. Always review surgical and pathology documentation to confirm the anatomic primary before code selection. Prostate cancer with seminal vesicle invasion (not primary origin) is still coded C61 — the distinction is primary tumor origin.
Excludes 2 — May Be Coded in Addition if Separately Present
| Code | Description | Note |
|---|---|---|
| Z85.46 | Personal history of malignant neoplasm of prostate | Would not be coded simultaneously with C61 in clinical logic, but listed here for awareness — use Z85.46 only when no active disease is present |
📋 Clinical Overview
Active Disease vs. History vs. In Situ
Understanding when to use C61 versus related codes is the single most impactful coding decision for prostate cancer encounters.
| Feature | C61 — Active Prostate Cancer | Z85.46 — History of Prostate Cancer | D07.5 — Carcinoma In Situ |
|---|---|---|---|
| Disease status | Active invasive malignancy present or under active tumor-directed treatment | Prior malignancy, no current active invasive disease | Non-invasive neoplastic cells confined to epithelium |
| Provider documentation | ”Prostate cancer,” “malignant neoplasm of prostate,” “prostatic adenocarcinoma" | "History of prostate cancer,” “status post prostatectomy, no evidence of disease" | "Prostatic intraepithelial neoplasia (PIN) — high grade” |
| HCC mapped (v28) | ✅ HCC 12 | ❌ No HCC weight | ❌ No HCC weight |
| Under active surveillance | Yes — if active disease acknowledged by provider | No | N/A |
| PSA rising post-treatment | Query provider for active vs. recurrence status | Add R97.21 if provider confirms biochemical recurrence | N/A |
CDI Query Trigger — Active Disease vs. Biochemical Recurrence
If the record notes a rising PSA after prostatectomy or radiation and the provider has not explicitly characterized disease status, a CDI query is warranted to confirm whether the patient has active recurrent prostate cancer (C61) or biochemical recurrence only (Z85.46 + R97.21). Active recurrence restores HCC 12 eligibility and changes the clinical picture significantly.
Manifestations & Common Comorbidities
Prostate cancer commonly presents with or results in the following documented conditions, each of which should be coded separately in addition to C61 when documented:
- Bone metastases: [[C79.51]] (bone), C79.52 (bone marrow) — the most common metastatic site for prostate cancer; bone lesions often drive the admission
- Lymph node metastases: C77.x — regional lymph node involvement
- Urinary obstruction: N13.x or N40.x — local tumor extension compressing the urethra or bladder neck
- Spinal cord compression: G99.2 — oncologic emergency from vertebral metastases; drives significant DRG weight
- Hormone sensitivity status: Z19.1 (hormone sensitive) or Z19.2 (hormone resistant/castration-resistant) — per ICD-10-CM instructional note under C61
- Rising PSA after treatment: R97.21 — per ICD-10-CM instructional note under C61
Code the Metastases — They're Not Optional
When the record documents metastatic prostate cancer, code each documented metastatic site separately. Bone metastases (C79.51) are extremely common and function as MCCs in the inpatient setting — capturing them directly affects DRG weight and reimbursement.
💰 HCC Risk Adjustment (CMS-HCC v28)
| Field | Detail |
|---|---|
| CMS-HCC Model Version | v28 (2024-2025 Implementation) |
| HCC Assignment | ✅ Mapped — HCC 12 |
| HCC Category | HCC 12 — Prostate Cancer, Lymphatic, and Other Urinary Cancers |
| RAF Coefficient | ~0.151 (varies by demographic/enrollment status) |
C61 maps to HCC 12 under CMS-HCC v28, reflecting the ongoing care resources required for active prostate cancer management including monitoring, ADT, imaging, and treatment of complications.
Capture Annually
HCC 12 must be supported by a provider-documented active diagnosis of malignant prostate neoplasm in the current calendar year. If C61 is replaced by Z85.46 (history) at any point without clinical justification for active disease, the HCC drops and risk-adjusted revenue decreases. Providers should document “prostate cancer” or “malignant neoplasm of prostate” at every encounter where active disease management is occurring, rather than defaulting to “history of prostate cancer.”
🏥 MS-DRG Assignment
MDC 12 — Diseases and Disorders of the Male Reproductive System
| DRG | Title | Est. Relative Weight* |
|---|---|---|
| DRG 715 | Other Male Reproductive System O.R. Procedure with MCC | ~3.80 - 4.50 |
| DRG 716 | Other Male Reproductive System O.R. Procedure with CC | ~2.00 - 2.50 |
| DRG 717 | Other Male Reproductive System O.R. Procedure without CC/MCC | ~1.30 - 1.60 |
| DRG 722 | Malignancy of Male Reproductive System with MCC | ~2.20 - 2.70 |
| DRG 723 | Malignancy of Male Reproductive System with CC | ~1.30 - 1.60 |
| DRG 724 | Malignancy of Male Reproductive System without CC/MCC | ~0.80 - 1.00 |
Approximate. Verify against IPPS FY2026 Final Rule tables.
Sequencing and DRG Routing
When C61 is the principal diagnosis without an O.R. procedure, the encounter typically groups to DRGs 722-724 (Malignancy of Male Reproductive System). When a surgical procedure such as radical prostatectomy is performed, the encounter routes to the O.R. DRGs (715-717). If metastatic disease is the driver of admission (e.g., bone metastases with spinal cord compression), it may be appropriate to sequence the complication as the principal diagnosis, which could route to MDC 08 (Musculoskeletal) or MDC 01 (Nervous System) depending on the documented reason for admission. Always sequence the reason for admission as principal per UHDDS guidelines.
🔗 Related ICD-10-CM Codes
Active Disease, History, and In Situ
| Code | Description |
|---|---|
| C61 | Malignant neoplasm of prostate ← This Code |
| D07.5 | Carcinoma in situ of prostate |
| Z85.46 | Personal history of malignant neoplasm of prostate |
| R97.21 | Rising PSA following treatment for malignant neoplasm of prostate |
Hormone Sensitivity Status (Add-On Codes)
| Code | Description |
|---|---|
| Z19.1 | Hormone sensitive malignancy status |
| Z19.2 | Hormone resistant malignancy status (castration-resistant) |
Common Metastatic Sites in Prostate Cancer
| Code | Description |
|---|---|
| C79.51 | Secondary malignant neoplasm of bone |
| C79.52 | Secondary malignant neoplasm of bone marrow |
| C77.5 | Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes |
| C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct |
| C79.31 | Secondary malignant neoplasm of brain |
🛠️ Commonly Associated CPT Codes (Urology / Oncology)
Inpatient and Outpatient Profee Setting Context
In the profee inpatient setting, urologists and oncologists managing prostate cancer typically bill E/M codes for daily management and surgical codes when procedures are performed. Outpatient management involves monitoring labs, imaging, and systemic therapy administration.
| CPT Code | Description | Profee Coding Notes |
|---|---|---|
| 55700 | Biopsy, prostate; needle or punch, single or multiple, any approach | Diagnostic; Modifier -26 if physician interpretation only; Modifier -25 on E/M if same day |
| 55866 | Laparoscopy, surgical prostatectomy, retropubic radical, including nerve sparing | Radical prostatectomy (robot-assisted often billed here); confirm with operative report |
| 55810 | Prostatectomy, perineal radical | Open perineal radical prostatectomy approach |
| 77427 | Radiation treatment management, 5 treatments | Used during external beam radiation treatment courses for prostate cancer |
| 96413 | Chemotherapy administration, IV infusion, initial up to 1 hour | Paired with C61 for chemotherapy infusion encounters |
| 86316 | Immunoassay for PSA, quantitative | Serial PSA monitoring; billed by lab |
NCCI Bundling Considerations
- 55700 (prostate biopsy) billed same day as an E/M requires Modifier -25 on the E/M code to demonstrate a significant, separately identifiable evaluation and management service.
- 77427 (radiation treatment management) is a global service — do not unbundle individual treatment sessions.
🔬 ICD-10-PCS Crosswalk (Inpatient Procedures)
When C61 is an inpatient diagnosis, these PCS codes are relevant for associated inpatient procedures.
| PCS Section | Body System | Root Operation | Clinical Application |
|---|---|---|---|
| 0 — Medical & Surgical | V — Male Reproductive | T — Resection | Radical prostatectomy (open): 0VT00ZZ; robotic-assisted laparoscopic: 0VT04ZZ |
| 0 — Medical & Surgical | V — Male Reproductive | B — Excision | Prostate biopsy, percutaneous needle: 0VB03ZX (open diagnostic) or 0VB04ZX (perc endoscopic diagnostic) |
| D — Radiation Therapy | V — Male Reproductive | 1 — Brachytherapy | Prostate brachytherapy (seed implantation), e.g., Palladium-103: DV108B0 |
| D — Radiation Therapy | V — Male Reproductive | 0 — Beam Radiation | External beam radiation therapy to prostate: DV100ZZ |
| 3 — Administration | E — Physiological Systems | 0 — Introduction | IV chemotherapy or ADT infusion via peripheral vein: 3E04305 |
💊 Coding Scenarios and Examples
Scenario 1 — Inpatient: Radical Prostatectomy for Localized Prostate Cancer
Clinical Vignette: A 64-year-old male with Gleason 7 (3+4) prostate adenocarcinoma, clinical stage T2b, hormone-sensitive, presents for elective robot-assisted laparoscopic radical prostatectomy. Pre-op PSA is 9.2 ng/mL. The surgeon performs a nerve-sparing robotic prostatectomy with pelvic lymph node dissection. Pathology confirms prostatic adenocarcinoma with negative margins. The patient is discharged on POD 2.
Principal Diagnosis:
- C61 — Malignant neoplasm of prostate (reason for admission — active prostate cancer)
Secondary Diagnoses:
- Z19.1 — Hormone sensitive malignancy status (per ICD-10-CM instructional note)
Procedure Codes (ICD-10-PCS):
- 0VT04ZZ — Resection of prostate, percutaneous endoscopic approach (robot-assisted laparoscopic radical prostatectomy)
MS-DRG Assignment: C61 principal + O.R. procedure (0VT04ZZ) → DRG 717 — Other Male Reproductive System O.R. Procedure without CC/MCC (no significant CC/MCC documented in this scenario).
Scenario 2 — Inpatient: Metastatic Prostate Cancer with Pathologic Spinal Fracture
Clinical Vignette: A 72-year-old male with known castration-resistant prostate cancer (on enzalutamide) presents with acute severe low back pain and bilateral lower extremity weakness. MRI spine reveals T10 vertebral metastasis with pathologic fracture and epidural extension causing cord compression. He is admitted to the oncology service for pain management, dexamethasone, and radiation oncology consultation.
Principal Diagnosis:
- C79.51 — Secondary malignant neoplasm of bone (reason for admission — pathologic fracture/cord compression from bone mets)
Secondary Diagnoses:
- C61 — Malignant neoplasm of prostate (primary tumor site — MCC as active malignancy)
- M84.58XA — Pathological fracture in neoplastic disease, vertebrae, initial encounter (MCC)
- G99.2 — Myelopathy in diseases classified elsewhere (cord compression — MCC)
- Z19.2 — Hormone resistant malignancy status (castration-resistant, per ICD-10-CM instructional note)
MS-DRG Assignment: C79.51 principal + multiple MCCs (C61, M84.58XA, G99.2) → routes to MDC 08 or MDC 17 depending on grouper — verify with FY2026 MS-DRG Definitions Manual.
Scenario 3 — CDI Query: “History of Prostate Cancer” on Active Treatment Note
Clinical Vignette: A 68-year-old male is admitted for a UTI. The admitting note documents “history of prostate cancer, currently on Lupron (leuprolide).” No further oncologic characterization is provided. The coder cannot determine whether this is an active malignancy managed with ADT or a treated/resolved malignancy in a patient simply continuing hormonal surveillance.
Action / Outcome: “History of prostate cancer” alone does not support C61 — it points toward Z85.46. However, active leuprolide (ADT) therapy strongly suggests ongoing active disease management. A CDI query should ask the provider to clarify whether prostate cancer is currently active and under treatment (supporting C61) or whether the ADT is being continued as adjuvant therapy after curative treatment with no active disease (potentially supporting Z85.46 with Z19.1).
Query Response: Provider updates documentation to confirm: “Patient has active, hormone-sensitive prostate cancer currently managed with androgen deprivation therapy.”
Corrected ICD-10-CM Coding:
- J32.9 or appropriate UTI code — Principal diagnosis (reason for admission)
- C61 — Active malignant neoplasm of prostate (comorbidity — confirmed active by provider)
- Z19.1 — Hormone sensitive malignancy status (per ICD-10-CM instructional note)
⚠️ Coding Pitfalls and Tips
| Pitfall or Tip | ||
|---|---|---|
| ❌ | Using C61 for history-only disease. “History of prostate cancer” without evidence of active disease or active tumor-directed treatment points to Z85.46, not C61. Always confirm active disease status with provider documentation before assigning C61. | |
| ❌ | Forgetting Z19.1/ Z19.2 add-on codes. ICD-10-CM includes an instructional note under C61 to use additional code(s) for hormone sensitivity status when documented. Omitting these codes is a guideline violation and misses clinical specificity. | |
| ❌ | Missing bone metastasis codes. Prostate cancer is notorious for bony metastases. If the record documents skeletal involvement and only C61 is assigned, the encounter is undercoded — C79.51 is a separate, frequently MCC-level secondary code. | |
| ✅ | Add R97.21 for rising PSA after treatment. ICD-10-CM specifically instructs coders to use R97.21 (rising PSA following treatment for malignant neoplasm of prostate) as an additional code when documented. This reflects biochemical recurrence and should not be overlooked. | |
| ✅ | Sequence metastatic site as principal when it drives admission. If the patient is admitted for a complication of metastatic prostate cancer (e.g., pathologic fracture, spinal cord compression), the complication or metastatic site may be the appropriate principal diagnosis per UHDDS guidelines — C61 would then sequence as a secondary code. | |
| ✅ | Annual HCC capture for Medicare Advantage patients. C61 maps to HCC 12 under CMS-HCC v28. Every calendar year, the active prostate cancer diagnosis must be documented and coded to maintain the HCC. Coordinate with CDI teams to flag patients on active ADT or oncology follow-up for annual recapture. |